Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02326974 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (NCT02326974)

Trial Description
This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2.

The names of the study interventions involved in this study are:

Ado-Trastuzumab Emtansine (T-DM1) (Kadcyla®; Genentech, Inc.)
Pertuzumab (Perjeta®; Genentech, Inc.)

This trial is sponsored by Dana-Farber Cancer InstituteNational Cancer Institute (NCI). [1]

Study Data

  • Condition:
    • HER-2 Positive Breast Cancer
    • Breast Cancer
    • Stage II Breast Cancer
    • Stage III Breast Cancer
  • Interventions:
    • Drugs used in this trial
    • Procedure: Excision of tumor/mastectomy
  • Phase: II
  • Estimated Enrollment: 160
  • Start: December 2014
  • Estimated Completion: April 2022
  • Last verified: July 27, 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 27, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar